𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment : Impact on survival and bleeding complications

✍ Scribed by Nicole M. Kuderer; Alok A. Khorana; Gary H. Lyman; Charles W. Francis


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
329 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

Preclinical evidence suggests that anticoagulants, in particular the low‐molecular‐weight heparins (LMWH), exert an antitumor effect, whereas clinical trials have reported conflicting results. The authors conducted a comprehensive, systematic review and meta‐analysis of the evidence from randomized controlled trials (RCTs), to evaluate the impact of anticoagulants on survival and safety in cancer patients without venous thromboembolism.

METHODS.

A comprehensive systematic literature review of RCTs was performed without language restrictions through May 2006 with subsequent updates to the end of 2006, including an exhaustive search of electronic databases, major conference proceedings, article references, and content experts. Two reviewers extracted data independently. Primary study outcomes were 1‐year overall mortality and all bleeding complications. Major and fatal bleeding complications were secondary outcomes.

RESULTS.

Across all 11 studies that were identified, anticoagulation significantly decreased 1‐year overall mortality with a relative risk (RR) of 0.905 (95% confidence interval [95% CI], 0.847–0.967; P = .003). The RR for mortality was 0.877 (95% CI, 0.789–0.975; P = .015) for LMWH, compared with an RR of 0.942 (95% CI, 0.854–1.040; P = .239) for warfarin, resulting in an absolute risk difference (ARD) of 8% for LMWH and an ARD of 3% for warfarin. Improved survival with anticoagulation may be dependent on tumor type. Major bleeding episodes occurred less frequently in patients who received LMWH (ARD, 1%) compared with patients who received warfarin (ARD, 11.5%; P < .0001). Overall, fatal bleeding occurred rarely (ARD, 0.32%; P = .542).

CONCLUSIONS.

Anticoagulants, particularly LMWH, significantly improved overall survival in cancer patients without venous thrombosis while increasing the risk for bleeding complications. However, given the limitations of available data, the use of anticoagulants as antineoplastic therapy cannot be recommended until additional RCTs confirm these results. Cancer 2007. © 2007 American Cancer Society.


📜 SIMILAR VOLUMES


Safety and Efficacy of the Endoscopic Mo
✍ Peter C. Anderson; Raj H. Sindwani 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

## OBJECTIVES: The endoscopic modifi ed Lothrop procedure (EMLP; also known as Draf III or frontal drillout) has recently gained popularity as a minimally-invasive alternative to frontal sinus obliteration. This systematic analysis was designed to assess the safety and effi cacy of the EMLP. STUDY

Safety and efficacy of the endoscopic mo
✍ Peter Anderson; Raj Sindwani 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

## Abstract ## Objectives/Hypothesis: The endoscopic modified Lothrop procedure (EMLP; also known as Draf III or frontal drillout) has recently gained popularity as a minimally invasive alternative to frontal sinus obliteration. This systematic analysis was designed to assess the safety and effica

Impact of axillary lymph node dissection
✍ Mona Sanghani; Ethan M. Balk; Blake Cady 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB 👁 2 views

## Abstract ## BACKGROUND: The regional lymph node control and survival impact of axillary dissection in breast cancer has been the subject of multiple randomized trials, with various results. This study reviews and conducts a meta‐analysis of contemporary trials of axillary dissection in patients

The clinical management of patients with
✍ Patricia Harnden; Brian Naylor; Michael D. Shelley; Hayley Clements; Bernadette 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 1 views

## Abstract Clinically localized prostate cancer is associated with a wide variation in biologic behavior, and men with the less aggressive form of the disease may never develop symptoms. There has been a rise in prostate cancer incidence in countries in which the blood test for prostatic‐specific